China's mRNA Shot Shows Benefits Over Older COVID Vaccines
Urgent Approval Warranted, Researchers Say
Executive Summary
Home-grown Chinese mRNA COVID-19 vaccines are more effective than domestic inactivated virus-based shots, new trial results show.
You may also be interested in...
Could New Data Herald China Approval For Comirnaty?
Long-term safety results from the mRNA COVID-19 vaccine’s Phase II trial in a Chinese population could pave the way for its approval in China, investigators say.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.